sorafenib has been researched along with nadp in 5 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (nadp) | Trials (nadp) | Recent Studies (post-2010) (nadp) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 21,608 | 25 | 3,484 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Manero, G; Hu, Y; Huang, P; Jiang, W; Lu, W; Tian, J; Wen, S; You, X; Yu, T; Zhang, H | 1 |
| Ai, Y; Cao, Y; Ma, Y; Sun, Q; Wang, J; Wang, X; Yan, B; Zhang, Z | 1 |
| Cai, N; Cheng, K; Liang, H; Wen, J; Xiong, Y; Zhang, W; Zhang, Y; Zhu, J | 1 |
| Luo, J; Mu, X; Wang, Z; Yang, Q; Zhao, Y | 1 |
| Li, Y; Liu, M; Wang, Z; Zhao, Y; Zheng, Y | 1 |
1 review(s) available for sorafenib and nadp
| Article | Year |
|---|---|
The Molecular Mechanisms of Regulating Oxidative Stress-Induced Ferroptosis and Therapeutic Strategy in Tumors.
Topics: Acetaminophen; Antineoplastic Agents; Antioxidants; Apoptosis; Artemisinins; Auranofin; Cell Death; Cisplatin; Epigenesis, Genetic; Fatty Acids; Ferroptosis; Haloperidol; Humans; Indoles; Iron; Lapatinib; Mevalonic Acid; NADP; Neoplasms; Oxidation-Reduction; Oxidative Stress; Oxygen; Quinolines; Reactive Oxygen Species; Sorafenib; Spiro Compounds; Sulfasalazine; Trigonella | 2020 |
4 other study(ies) available for sorafenib and nadp
| Article | Year |
|---|---|
Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carbon Isotopes; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Glucose; Glutathione; Humans; Leukemia; Mass Spectrometry; Metabolomics; Mice; NADP; Oxidation-Reduction; Pentose Phosphate Pathway; Protein Kinase Inhibitors; Sorafenib | 2019 |
Membrane Damage during Ferroptosis Is Caused by Oxidation of Phospholipids Catalyzed by the Oxidoreductases POR and CYB5R1.
Topics: Animals; Cell Line, Tumor; Cell Membrane; Concanavalin A; Cytochrome P-450 Enzyme System; Cytochrome-B(5) Reductase; Electron Transport; Fatty Acids, Unsaturated; Ferroptosis; HEK293 Cells; HeLa Cells; Humans; Hydrogen Peroxide; Lipid Peroxidation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; NADP; Oxygen; Phenylurea Compounds; Piperazines; Pyridines; Sorafenib | 2021 |
Hypoxia-responsive nanocarriers for chemotherapy sensitization via dual-mode inhibition of hypoxia-inducible factor-1 alpha.
Topics: Antineoplastic Agents; Aspartic Acid; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cytochromes c; Dicumarol; Female; Glutathione; Humans; Hypoxia; Micelles; NAD; NADP; Nitroimidazoles; Oxygen; Phosphates; Polyethylene Glycols; Polymers; Quinones; Sorafenib; Thioredoxins | 2022 |
Coenzyme-depleting nanocarriers for enhanced redox cancer therapy under hypoxia.
Topics: Animals; Antioxidants; Cell Line, Tumor; Coenzymes; Glutathione; Humans; Hypoxia; Mice; NADP; Neoplasms; Nitroimidazoles; Oxidation-Reduction; Sorafenib | 2023 |